Background
==========

Esophageal squamous cell carcinoma (ESCC) has attracted much research attention around the world, and the number of ESCC cases has increased gradually in recent years. Xinjiang is the highest-incidence area of esophageal cancer in China \[[@b1-medscimonit-21-2659]\]. Esophageal cancer mortality is 68.88/100 000 in the Kazakh ethnic group and is a serious threat to people's health. Lv Xiuping et al. \[[@b2-medscimonit-21-2659]\] studied the differentially expressed proteins between human normal esophageal epithelial cells (NEEC) and esophageal squamous cell carcinoma cells. The proteins of the cells were separated by 2-dimensional gel electrophoresis (2-DE) and analyzed using ImageMASTER 2D software. Differential proteins between NEEC and ESCC cells were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). As a result, 43 protein spots were discovered and 15 were up-regulated. Zhang et al. \[[@b3-medscimonit-21-2659]\] also found obvious up-regulation of Bmi-1 in ESCC cells. This study aimed to determine the expressions of Cofilin-1 and transgelin in 68 cases of esophageal squamous cell carcinoma (ESCC) by using SP method, and to statistically analyze the expressions of Cofilin-1 and transgelin and clinical pathological characteristics of ESCC \[[@b4-medscimonit-21-2659],[@b5-medscimonit-21-2659]\].

Material and Methods
====================

Study population and materials
------------------------------

The study was conducted at the First Affiliated Hospital of Xinjiang Medical University. We selected ESCC tissue specimens from 68 patients between 2012 and 2014. All specimens were obtained following surgical resection and were proved by pathologists. Of these 68 patients, there were 35 males and 33 females; 16 were under age 50 years and 52 were over 50; 36 were of Kazak ethnicity and 32 were Han ethnicity; 27 had tumor size less than 5 cm and 41 had tumors 5 cm or greater in size; 24 patients had tumors with high differentiation, 33 had moderate differentiation, and 11 had low differentiation; 6 patients had tumors infiltrating the esophageal mucosa and submucosa, 27 patients had tumors that infiltrated the muscular layer and 35 patients had them in the placenta percreta layer; 52 patients experienced lymphatic metastasis and 16 did not. Additionally, we enrolled 48 individuals with normal tissues and recorded basic information including sex, age, and ethnicity. Specimens were collected, read, and analyzed by 2 experienced pathologists. The study was funded by the Natural Science Foundation of Xinjiang and was reviewed by the medical ethics committee of our hospital. All participants acknowledged and signed the informed consent documents.

Study design
------------

SP immunohistochemical method was used to determine the expression of Cofilin-1 and transgelin in 68 patients. The immunohistochemical EnVision 2 footwork method was used to determine the protein expression of Cofilin-1 and transgelin in each group.

Interpretation of the results
-----------------------------

Positive Cofilin-1 and transgelin expression was indicated by tan or brown granular particles in the cytoplasm. Expression in normal esophageal mucosa cells was used as a positive control.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS17.0 software for analyzing sex, age, ethnicity, size of tumor, degree of differentiation, depth of infiltration, and lymphatic metastasis, and we used the χ^2^ test. Inspection level α=0.05, P\<0.05 was considered statistically significant.

Results
=======

Expression of Cofilin-1 and transgelin in ESCC and normal esophageal tissue
---------------------------------------------------------------------------

The expression of Cofilin-1 in ESCC refers is shown in [Figure 1](#f1-medscimonit-21-2659){ref-type="fig"}. The rates of expression of Cofilin-1 in esophageal cancer tissue and normal tissue were 60.3% (41/68) and 27.1% (13/48), respectively. The difference in rates was statistically significant between cancer tissue and normal tissue (P\<0.05) ([Table 1](#t1-medscimonit-21-2659){ref-type="table"}).

The expression of transgelin in ESCC is shown in [Figure 2](#f2-medscimonit-21-2659){ref-type="fig"}. The rates of expression of transgelin in esophageal cancer tissue and normal tissue were 54.4% (37/68) and 29.1% (14/48), respectively. The difference in rates was statistically significant between cancer tissue and normal tissue (P\<0.05) ([Table 2](#t2-medscimonit-21-2659){ref-type="table"}).

Relationship between Cofilin-1 and transgelin expression and clinical pathological parameters
---------------------------------------------------------------------------------------------

The differences of Cofilin-1 positive expression rates in patients with low, moderate, or high differentiation were statistically significant (P\<0.05), which indicates that Cofilin-1 expression gradually increased with higher degree of differentiation. The differences in Cofilin-1 expression rates in patients with lymphatic metastasis and without lymphatic metastasis were statistically significant (P\<0.05), showing that there is a relationship between Cofilin-1 expression and lymphatic metastasis. At clinical stages I--II and III--IV the positive expression of Cofilin-1 was 37.9% and 76.9%, respectively and the differences were statistically significant (P\<0.05). The results indicated that the expressions of Cofilin-1 probably were closely related to clinical stages. Cofilin-1 expression in ESCC was not correlated with sex, age, ethnicity, tumor size, or depth of infiltration. There was no significant difference in expression (P\>0.05) ([Table 3](#t3-medscimonit-21-2659){ref-type="table"}).

The transgelin-positive expression rates in patients with low, moderate, or high differentiation were 37.5%, 57.6%, and 81.8%, respectively and the differences were statistically significant (P\<0.05), indicating that transgelin plays an important role in cell differentiation. Transgelin expression in patients without lymphatic metastasis and in those with lymphatic metastasis was 18.8% and 65.4%, respectively. The difference was statistically significant (P\<0.05), which shows that transgelin expressions were higher in patients with lymphatic metastasis. At clinical stages I--II and III--IV, the positive expression of transgelin was 44.8% and 61.5%, respectively, but the difference was not statistically significant (P\>0.05). The results indicate that transgelin expression in ESCC has no relationship with sex, age, ethnicity, depth of infiltration, clinical stages, or tumor size (P\>0.05) ([Table 4](#t4-medscimonit-21-2659){ref-type="table"}).

Discussion
==========

It is well known that esophageal squamous cell carcinoma (ESCC) is prone to invade adjacent regions and to metastasize to lymph nodes \[[@b6-medscimonit-21-2659]\]. In this study, we identified and functionally characterized Cofilin-1 as an important participant in ESCC progression.

Cofilin-1 is one of the main proteins in charge of cell motility; it is regulated by many factors, such as binding of phosphoinositides, phosphorylation, and subcellular compartmentalization \[[@b7-medscimonit-21-2659],[@b8-medscimonit-21-2659]\]. Local activation of Cofilin-1 by uncaging induces lamellipod formation and sets the direction of cell motility \[[@b9-medscimonit-21-2659],[@b10-medscimonit-21-2659]\]. The over-expression of cofilin can increase the velocity of cell migration in dictyostelium and in human glioblastoma cells \[[@b11-medscimonit-21-2659],[@b12-medscimonit-21-2659]\]. Cofilin-1 is a key factor in cell cycle regulation and plays crucial roles in the pathogenesis and development of neoplasms \[[@b13-medscimonit-21-2659],[@b14-medscimonit-21-2659]\]. The over-expression of Cofilin-1 has been detected in the invasive tumor cells in cervical cancer, liver cancer, colon cancer, gastric cancer, pancreatic cancer, and kidney cancer \[[@b15-medscimonit-21-2659]--[@b18-medscimonit-21-2659]\]. It was found that up-regulated expression of Cofilin-1 was the main factor in determining the poor prognosis of pulmonary adenocarcinoma \[[@b19-medscimonit-21-2659],[@b20-medscimonit-21-2659]\].

Few studies have investigated the correlation between Cofilin-1 and ESCC. Jones et al. \[[@b21-medscimonit-21-2659]\] found that, in normal gastric mucosa tissue, the expression of Cofilin-1 is low; however, its expression increases in cancer tissue. The results prove that Cofilin-1 has a close relationship with gastric carcinoma. In our study, Cofilin-1 expression in ESCC was shown to be related with patients' degree of differentiation, lymphatic metastasis, and clinical stages. Cofilin-1 expression was significantly up-regulated in ESCC tissues compared with adjacent non-cancerous tissues. However, patient ethnicity had no effect on Cofilin-1 expression. The results indicate that Cofilin-1 plays a role in the carcinogenesis and development of esophageal squamous cell carcinoma, and it may help determine the degree of malignancy in carcinoma. Further studies are needed to determine whether Cofilin-1 can be used as a pre-diagnosis indicator for esophageal squamous cell carcinoma; whether the expression of Cofilin-1 is closely related with drug resistance; and whether it can be used as a parameter to guide individual chemotherapy.

Transgelin, also known as smooth muscle-22α, directly binds to the actin cytoskeleton and induces actin bundling to facilitate the formation of cytoskeletal structures such as stress fibers \[[@b22-medscimonit-21-2659]\]. Transgelin has been shown to stabilize loose actin gels, leading to actin filament gelation. It is one of the earliest markers of smooth muscle differentiation and has been implicated in many biologic activities, including regulating muscle fiber contractility, cell differentiation, tissue invasion, and tumor suppression \[[@b23-medscimonit-21-2659]\]. For many years, its function was unknown. Previous studies have shown that transgelin is an actin-binding protein considered a marker of smooth muscle differentiation, and is upregulated in podocytes in several models of podocyte disease \[[@b24-medscimonit-21-2659]\]. Studies have shown that reduced transgelin levels have a proliferative effect in vascular smooth muscle cells and prostate tumor cells, and that transgelin levels were significantly reduced in proliferating cells in prostate, lung, breast, glioblastoma, and colorectal cancers \[[@b25-medscimonit-21-2659]--[@b28-medscimonit-21-2659]\]. Studies have reported the over-expression of transgelin protein in lung cancer, gallbladder cancer, and liver cancer tissue \[[@b29-medscimonit-21-2659],[@b30-medscimonit-21-2659]\]. Several studies have been reported varying results \[[@b31-medscimonit-21-2659]\], and our research team hopes conduct another study with larger sample size in the near future.

To the best of our knowledge, there are few studies on the relationship between transgelin and ESCC. In the present study, we demonstrated that transgelin over-expression in ESCC was correlated with differentiation degree and lymph node metastasis. The results indicate that transgelin is related to the occurrence and development of ESCC. The detection of transgelin is valuable in early diagnosis of esophageal squamous cell carcinoma. However, other studies have reported conflicting results and more experiments are needed to confirm our findings. Identification of transgelin as the specific biomarker of ESCC is an effective approach for the early diagnosis of tumors. Further studies are needed to better delineate and to provide functional proof of this deduction.

Conclusions
===========

In summary, our results indicate that the role of Cofilin-1 and transgelin in esophageal squamous cell carcinoma is different from that of Cofilin-1 and transgelin in other neoplasms. To study the expression of different proteins will add to the foundation of target gene therapy of esophageal squamous cell carcinoma. Treatment and estimating prognosis of esophageal squamous cell carcinoma has received much research attention \[[@b32-medscimonit-21-2659]--[@b34-medscimonit-21-2659]\]. Moreover, it also provided a molecular basis for the clinical diagnosis and therapy targeted in this signaling pathway. Further studies are needed to determine if Cofilin-1 and transgelin can be used as pre-diagnosis indicators for esophageal squamous cell carcinoma. Although Cofilin-1 and transgelin may not be independent prognostic factors, they warrant further prospective analysis and more comprehensive study in esophageal squamous cell carcinoma.
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###### 

Cofilin-1 protein expression in esophageal cancer and normal esophageal tissues.

  Pathological characteristic   Total cases   Positive   Negative   Positive rate (%)   χ^2^     *P* value
  ----------------------------- ------------- ---------- ---------- ------------------- -------- -----------
  Cancerous tissue              68            41         27         60.3                12.473   0.001
  Normal tissue                 48            13         35         27.1                         

###### 

Transgelin protein expression in esophageal cancer and normal esophageal tissues.

  Pathological characteristic   Total cases   Positive   Negative   Positive rate (%)   χ^2^    *P* value
  ----------------------------- ------------- ---------- ---------- ------------------- ------- -----------
  Cancerous tissue              68            37         31         54.4                7.279   0.006
  Normal tissue                 48            14         34         29.1                        

###### 

Correlation between Cofilin-1 expression and clinicopathological data.

  Characteristics          Total cases   Positive cases   Positive rate (%)   χ^2^     *P* value
  ------------------------ ------------- ---------------- ------------------- -------- -----------
  Sex                                                                                  
   Male                    35            23               65.7                0.885    0.347
   Female                  33            18               54.5                         
  Age (yr)                                                                             
   \<50                    16            12               75.0                1.890    0.169
   ≥50                     52            29               55.8                         
  Nationality                                                                          
   Kazakh                  36            22               61.1                0.021    0.884
   Han                     32            19               59.4                         
  Tumor size(cn)                                                                       
   \<5                     27            18               66.7                0.760    0.383
   ≥5                      41            23               56.1                         
  Differentiation degree                                                               
   High                    24            8                33.3                11.546   0.003
   Moderate                33            24               72.7                         
   Low                     11            9                81.8                         
  Depth of infiltration                                                                
   Mucosal & submucosa     6             3                50.0                0.948    0.622
   Muscular layer          27            15               55.6                         
   Placenta percreta       35            23               65.7                         
  Lymphatic metastasis                                                                 
   No                      16            4                25.0                10.887   0.001
   Yes                     52            37               71.1                         
  Clinical stages                                                                      
   Stage I--II             29            11               37.9                10.563   0.001
   Stage III--IV           39            30               76.9                         

###### 

Correlation between transgelin expression and clinicopathological data.

  Characteristics          Total cases   Positive cases   Positive rate (%)   χ^2^     *P* value
  ------------------------ ------------- ---------------- ------------------- -------- -----------
  Sex                                                                                  
   Male                    35            20               57.1                0.217    0.641
   Female                  33            17               51.5                         
  Age (yr)                                                                             
   \<50                    16            12               75.0                3.575    0.059
   ≥50                     52            25               48.1                         
  Nationality                                                                          
   Kazakh                  36            21               58.3                0.474    0.491
   Han                     32            16               50.0                         
  Tumor size(cn)                                                                       
   \<5                     27            15               55.6                0.024    0.878
   ≥5                      41            22               53.7                         
  Differentiation degree                                                               
   High                    24            9                37.5                6.231    0.044
   Moderate                33            19               57.6                         
   Low                     11            9                81.8                         
  Depth of infiltration                                                                
   Mucosal & submucosa     6             2                40.0                1.194    0.55
   Muscular layer          27            15               55.6                         
   Placenta percreta       35            20               57.1                         
  Lymphatic metastasis                                                                 
   No                      16            3                18.8                10.727   0.001
   Yes                     52            34               65.4                         
  Clinical stages                                                                      
   Stage I--II             29            13               44.8                1.872    0.171
   Stage III--IV           39            24               61.5                         
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